Focus sur le tirzépatide, un double agoniste unimoléculaire GIP-GLP-1 dans le diabète de type 2
Tirzepatide’s effects on blood sugar control in type 2 diabetes
AI simplified
Abstract
Tirzepatide demonstrated greater reductions in HbA1c and body weight in a dose-dependent manner (5, 10, and 15 mg) compared to placebo and other treatments.
- Tirzepatide is a dual agonist targeting GIP and GLP-1 receptors.
- Efficacy was superior to placebo, basal insulin, and two GLP-1 analogues (dulaglutide and semaglutide) in the SURPASS program.
- Ongoing testing in the SURPASS-CVOT is evaluating cardiovascular protection compared to dulaglutide.
- Additional studies are underway for its use in treating obesity and metabolic associated fatty liver disease.
- Gastrointestinal side effects are comparable to GLP-1 analogues, with increased reports of diarrhoea.
AI simplified